Lazyweb
LionBio TherapeuticsSR007 landing page report.
← Back to the SR007 rankings
LionBio Therapeuticshttps://lion.bio/

Your landing page’s weakest score is Trust.

Fix Trust
Lazyweb ProAI Growth PMTurn this score into growth.Analyze your site and propose fixes across conversion, SEO, and AEOMonitor competitors’ in-product UX and A/B testsLearn from growth experiments across 10,000+ top productsTry Pro Free

Score over time

8070605040Rani Therapeutics 61 on Mar 11 (Wayback)Rani Therapeutics 63 on Mar 19 (Wayback)Rani Therapeutics 60 on Apr 26 (Wayback)Rani Therapeutics 58 on May 9 (Wayback)Rani Therapeutics 62 on May 21 (Wayback)Rani Therapeutics 74 on Jul 23 (Wayback)Rani Therapeutics 74 on Jul 27 (Live)Entera Bio 61 on Jul 27 (Live)Oramed Pharmaceuticals 48 on Mar 9 (Wayback)Oramed Pharmaceuticals 49 on Mar 23 (Wayback)Oramed Pharmaceuticals 49 on Apr 17 (Wayback)Oramed Pharmaceuticals 49 on May 6 (Wayback)Oramed Pharmaceuticals 49 on May 18 (Wayback)Oramed Pharmaceuticals 48 on Jun 18 (Wayback)Structure Therapeutics 46 on Feb 10 (Wayback)Structure Therapeutics 53 on Jul 27 (Live)LionBio Therapeutics 75 on Jul 27 (Live)Jul 27

Trust

64Fair

Proof that the product is real, competent, and safe to try.

LionBio Therapeutics
Rani Therapeutics
Trust read
LionBio Therapeutics"Columbia — University spinout technology" credential in the stats strip
Rani Therapeutics"3 Phase 1 studies completed" stat badge
Entera BioNo visible trust signal identified.
Oramed PharmaceuticalsNo visible trust signal identified.
Structure TherapeuticsNo visible trust signal identified.

Information hierarchy

73Fair

Does the design help or inhibit what the page is trying to say?

Information hierarchy annotations on the desktop capture123
  1. Explore our research — Dark green on black hero gives the primary CTA the lowest contrast of any button on the page.
  2. View open roles — White secondary button outshines the primary CTA at equal size, splitting the click between two actions.
  3. Careers nav pill — Reuses the primary CTA's green fill, pulling first-glance attention to the top-right exit.

CTA

76Fair

Copy, size, verb, cost-feel — does the primary CTA earn the click?

LionBio Therapeutics

Problems

  • 'Explore' is a soft, vague verb
  • no header echo of GLP-1 hook
  • payoff of the click is unclear

Mobile web

78Fair

The phone experience as a first-class citizen.

Mobile web annotations on the mobile capture1234
  1. Top nav link row — Desktop pill links (Team/Research/Blog/Careers) are crammed in uncollapsed instead of a hamburger menu.
  2. Explore our research button — Primary CTA floats at roughly half the column width instead of a full-bleed, thumb-friendly bar.
  3. Hero headline — Serif headline scales up too far, wrapping into four lines and eating a quarter of the fold.
  4. View open roles button — Secondary CTA is styled at near-equal weight and stacks directly under the primary, splitting the tap decision.

Value props

82Strong

Title, subtitle, hero — do they sell the product's true value?

LionBio Therapeutics’s headline sellsThe world's first GLP-1s taken through your nose.Direct-to-brain and less nausea. Next gen intranasal peptide therapeutics powered by our precision nanoparticle technology.

Working

  • World-first claim is concrete and instantly parseable
  • 'Less nausea' targets the category's real pain point
  • 30+ years IP and Columbia spinout add credibility

Could improve

  • 'Less nausea' has no supporting number
  • Hero render decorates, doesn't show mechanism
  • No development stage or trial status shown

Graded against Lazyweb’s growth rubrics.